Engineering better immunotherapies via RNA interference

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3165-3174

  Sioud, Mouldy ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer vaccine; Gene silencing; Immunotherapy; RNA interference; T cell therapy; Targeted therapies

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; GENE SILENCING; HUMAN; IMMUNOGENICITY; MELANOMA B16; NONHUMAN; NUCLEAR REPROGRAMMING; OVARY CANCER; REGULATORY T LYMPHOCYTE; RNA INTERFERENCE; ADOPTIVE IMMUNOTHERAPY; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES;

EID: 84921734612     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29754     Document Type: Article

References (75)

1. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464-78; PMID:21029958; http://dx.doi.org/10.1016/j.immuni.2010.10.007
2. Liu K, Nussenzweig MC. Origin and development of dendritic cells. Immunol Rev 2010; 234:45-54.
3. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4:336-47; PMID:15122199; http://dx.doi.org/10.1038/nri1349
4. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71:1065-8; PMID:1335362; http://dx.doi.org/10.1016/S0092-8674(05)80055-8
5. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interaction between PD-1 and PD-L-1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10:1185-92; PMID:19783989; http://dx.doi.org/10.1038/ni.1790
6. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Fox3+ C regulatory T cell function. Science 2008; 322:271-5; PMID:18845758; http://dx.doi.org/10.1126/science.1160062
7. Munn DH, Mellor AL. Indolamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 17:1147-54; PMID:17476344; http://dx.doi.org/10.1172/JCI31178
8. Corinti S, Albanesis C, la Salsa A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001; 166:4312-20; PMID:11254683; http://dx.doi.org/10.4049/jimmunol.166.7.4312
9. Rettig GR, Behlke MA. Progress toward in vivo use of siRNAs-II. Mol Ther 2012; 20:483-512; PMID:22186795; http://dx.doi.org/10.1038/mt.2011.263
10. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNAshRNA therapeutics in clinical trials. Biotechnol J 2011; 6:1130-46; PMID:21744502; http://dx.doi.org/10.1002/biot.201100054
11. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5; PMID:15372042; http://dx.doi.org/10.1038/nature02871
12. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040
13. Letterio JJ, Bottinger EP. TGF-beta knockout and dominant negative receptor transgenic mice. Miner Electrolyte Metab 1998; 24:161; PMID:9525700; http://dx.doi.org/10.1159/000057365
14. Marine JC. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999; 98:609-16; PMID:10490100; http://dx.doi.org/10.1016/S0092-8674(00)80048-3
15. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdc1- mice as efficient animal model of type I diabetes. Proc Acad Sci USA 2005; 102:11823-8; PMID:16087865; http://dx.doi.org/10.1073/pnas.0505497102
16. Munn DH, Mellor AL. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-74; PMID:15459668; http://dx.doi.org/10.1038/nri1457
17. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in draining-draining lymph noedes. J Clin Invest 2004; 114:280-90; PMID:15254595; http://dx.doi.org/10.1172/JCI200421583
18. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosies by tryptophan catabolism. Cell Death Differ 2002; 9:1069-77; PMID:12232795; http://dx.doi.org/10.1038/sj.cdd.4401073
19. Furset G, Floisand Y, Sioud M. Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-78 ligands. Immunology 2007; 123:263-71; PMID: 17725606
20. Wobster M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, Kaempgen E, Schrama D, Becker JC. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 2007; 56:1017-24; PMID:17195079; http://dx.doi.org/10.1007/s00262-006-0256-1
21. Flatekval GF, Sioud M. Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology 2009; 128:e837-48; PMID:19740345; http://dx.doi.org/10.1111/j.1365-2567.2009.03093.x
22. Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N, Navarro B, Ichim TE, Urquhart B, Min W. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer 2013; 132:967-77.
23. Sioud M, Saeboe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G. Silencing of indoleamine 2,3-dioxygenase in dendritic cell cancer vaccines: evaluation in vitro and in cancer patients. Int J Oncol 2013; 43:280-8; PMID:23620105
24. Sæbo-Larsen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002; 259:191-203; PMID:11730854; http://dx.doi.org/10.1016/S0022-1759(01)00506-3
25. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005;17:399-411; PMID:16149282; http://dx.doi.org/10.1016/j.clon.2005.05.009
26. Kubo M, Handa T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4:1169-76; PMID:14639467; http://dx.doi.org/10.1038/ni1012
27. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004; 22:1546-52; PMID:15558048; http://dx.doi.org/10.1038/nbt1035
28. Song XT, Evel-Kabler, K, Rollins L, Aldrich M, Gao F, Huang XF, Chen SY. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 3:e11; PMID:16381597; http://dx.doi.org/10.1371/journal.pmed.0030011
29. Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi AO, Uluda-g H, Lavasanifar A. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. Molec Pharmaceut 2010; 7:1643-54; PMID:20804176; http://dx.doi.org/10.1021/mp100067u
30. Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G, Foster BA, Subjeck JR, Sun X, Mikkelsen RB, Fisher PB, Wang XY. In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy. Mol Cancer Ther 2012; 11:2012; 2331-39; PMID:22896667; http://dx.doi.org/10.1158/1535-7163.MCT-12-0164
31. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
32. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2011; 11:1354-9; PMID:21154117
33. Hobo W, Novobrantseva TI, Fredrix H, Wong J, Milstein S, Epstein-Barash H, Liu J, Schaap N, van der Voort R, Dolstra H. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 2013; 62:285-97; PMID:22903385; http://dx.doi.org/10.1007/s00262-012-1334-1
34. Rabinovich GA, Toscano MA. Turning "sweet" on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009; 9:338-52; PMID:19365409; http://dx.doi.org/10.1038/nri2536
35. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin 1: a small protein with major functions. Glycobiology 2006; 16:137-57; PMID:16840800; http://dx.doi.org/10.1093/glycob/cwl025
36. Hsu DK, Chen HY, Liu FT. Galectin-3 regulates T-cell functions. Immunol Rev 2009; 230, 114-27.
37. Mobergslien A, Sioud M. Galectin-1 and -3 gene silencing in immature and mature dendritic cells enhances T cell activation and interferon-g production. J Leucocyte Biol 2012; 91:461-7; PMID:22167721Z; http://dx.doi.org/10.1189/jlb.0711361
38. Grossman Z, Singer A. Tuning of activation threshold explains flexibility in the selection and development of T cells in the thymus. Proc Acad Sci USA 1996; 93:14747-52; PMID:8962126; http://dx.doi.org/10.1073/pnas.93.25.14747
39. Cekaite L, Furset G, Hvig E, Sioud M. Gene expression analysis in blood cells in response to umpdified and 2'-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 2007; 365:90-108; PMID:17054988; http://dx.doi.org/10.1016/j.jmb.2006.09.034
40. Maldonado-Lopz R, Maliszewski C, Urbain J, Moser M. Cytokines regulates the capacity of CD8 alpha (+) and CD8 alpha (-) dendritic cells to prime Th1Th2 cells in vivo. J Immunol 2001; 167:4345-50; PMID:11591758; http://dx.doi.org/10.4049/jimmunol.167.8.4345
41. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, Mantovani A. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Avd Exp Med Biol 1997; 417:323-9; PMID:9286381; http://dx.doi.org/10.1007/978-1-4757-9966-8-53
42. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348:1079-10; PMID:15854645; http://dx.doi.org/10.1016/j.jmb.2005.03.013
43. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G. Sequnece-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70; PMID:15723075; http://dx.doi.org/10.1038/nm1191
44. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-62; PMID:15778705; http://dx.doi.org/10.1038/nbt1081
45. Furset G, Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Comm 2007; 352:642-9; PMID:17150189; http://dx.doi.org/10.1016/j.bbrc.2006.11.059
46. Iversen PO, Semaeva E, Sorensen DR, Wiig H, Sioud M. Dendritic cells loaded with tumor antigens and a dual immunostimulatory and anti-interleukin 10-specific small interference RNA prime T lymphocytes against leukemic cells. Transl Oncol 2009; 2:242-6; PMID:19956385; http://dx.doi.org/10.1593/tlo.09154
47. Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials 2014; 35:5491-504; PMID:24720881; http://dx.doi.org/10.1016/j.biomaterials.2014.03.039
48. Chhabra A, Chakraborty NG, Mukherji B. Scilencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-127-35. Clin Immunol 2008; 126:251-9; PMID:18249038; http://dx.doi.org/10.1016/j.clim.2007.11.011
49. Glas M, Coch C, Trageser D, Dassler J, Simon M, Koch P. Targeting the cytosolic innate immune receptors RIG-1 and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells 2013; 31:1064-74; PMID:23390110; http://dx.doi.org/10.1002/stem.1350
50. Kübler K, Gehrke N, Riemann S, Böhnert V, Zillinger T, Hartmann E, Pölcher M, Rudlowski C, Kuhn W, Hartmann G, Barchet W. Targeted activation of RNA helicase retinoic acid-inducible gene-1 induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 2010; 70:5293-304; PMID:20551064; http://dx.doi.org/10.1158/0008-5472.CAN-10-0825
51. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, et al. 5'-triphosphate-siRNA: turning gene silencing and RIG-1 activation against melanoma. Nat Med 2008; 14:1256-63; PMID:18978796; http://dx.doi.org/10.1038/nm.1887
52. Ali OA, Emerich D, Dranoff G, Mooney DJ. In situ regulation of DC subsets and T cells mediated tumor regression in mice. Sci Transl Med 2009; 8:8-19; PMID:20368186; http://dx.doi.org/10.1126/scitranslmed.3000359
53. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on manor histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi.org/10.1084/jem.20021598
54. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B,Moran TM, Steinman RM. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
55. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 2006; 211:599-608; PMID:16920498; http://dx.doi.org/10.1016/j.imbio.2006.05.021
56. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:15878980; http://dx.doi.org/10.1182/blood-2005-01-0318
57. Sioud M, Skorstad G, Mobergslien A, Sæboe-Larssen S. A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells. FASEB J 2013; 27:3272-83; PMID:23671272; http://dx.doi.org/10.1096/fj.12-224758
58. Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J, et al. Leukemia cell-targeted STAT3 silencing and TLR9-triggering generate systemic antitumor immunity. Blood 2014; 123:15-25; PMID:24169824; http://dx.doi.org/10.1182/blood-2013-07-517987
59. Nurieva R, Wang J, Sahoo A. T-cell tolerance in cancer. Immunotherapy 2013; 5:513-31; PMID:23638746; http://dx.doi.org/10.2217/imt.13.33
60. June,CH. Adoptive T cell therapy for cancer in the clinic. J. Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
61. Rosenberg SA., Restifo, NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-30; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
62. Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, et al. microRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013; 38:742-53; PMID:23601686; http://dx.doi.org/10.1016/j.immuni.2012.12.006
63. Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, et al. Role of STAT3 in CD4+ CD25 +FOXP3+ regulatory lymphocyte generation: implication in graft-versus-host disease and antitumor immunity. J Immunol 2007; 179:7593-604; PMID:18025205; http://dx.doi.org/10.4049/jimmunol.179.11.7593
64. Moriwaki A, Inoue H, Nakano T, Matsunaga Y, Matsuno Y, Matsumoto T, Fukuyama S, Kan-O K, Matsumoto K, Tsuda-Eguchi M, et al. T cell treatment with small interfering RNA for suppressor of cytokine signaling 3 modulates allergic airway responses in a murine model of asthma. Am J Respir Cell Mol Biol 2011; 44:448-55; PMID:20508071; http://dx.doi.org/10.1165/rcmb.2009-0051OC
65. Pike KA, Tremblay ML. Regulating naive and memory CD8 T cell homeostasis - a role for protein tyrosine phosphatases. FEBS J 2013; 280:432-44; PMID:22458809; http://dx.doi.org/10.1111/j.1742-4658.2012.08587.x
66. Jeon MS, Atfield A, Venuprasad K, Krawczyk C, Sarao R, Elly C, Yang C, Arya S, Bachmaier K, et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004; 21:167-77; PMID:15308098; http://dx.doi.org/10.1016/j.immuni.2004.07.013
67. Hinterleitner R, Gruber T, Pfeifhofer-Obermair C, Lutz-Nicoladoni C, Tzankov A, Schuster M, Penninger JM, Loibner H, Lametschwandtner G, Wolf D, et al. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumour vaccine Efficacy in a B16 melanoma model. PLOS One 2012; 7:e44295; PMID:22962608; http://dx.doi.org/10.1371/journal.pone.0044295
68. Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, et al. Abrogation of Src homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. J Immunol 2012; 189:1812-25; PMID:22798667; http://dx.doi.org/10.4049/jimmunol.1200552
69. Sathish JG, Dolton G, Leroy FG, Matthews RJ. Loss of Src homology region 2 domain-containing protein tyrosine phosphatase-1 increases CD8+ T cell-APC conjugate formation and is associated with enhanced in vivo CTL function. J Immunol 2007; 178:330-7; PMID:17182570; http://dx.doi.org/10.4049/jimmunol.178.1.330
70. Mantei A, Rutz S, Janke M, Kirchhoff D, Jung U, Patzel V, Vogel U, Rudel T, Andreou I, Weber M, Scheffold A. siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur J Immunol 2008; 38:2616-25; PMID:18792414; http://dx.doi.org/10.1002/eji.200738075
71. Burnett JC., Zaia JA, Rossi JJ. Creating genetic resistance to HIV. Curr Opin Immunol 2012; 24, 625-32; PMID:22985479; http://dx.doi.org/10.1016/j.coi.2012.08.013
72. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23:709-17; PMID:15908939; http://dx.doi.org/10.1038/nbt1101
73. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134:577-86; PMID:18691745; http://dx.doi.org/10.1016/j.cell.2008.06.034
74. Lebbink RJ, Lowe M, Chan T, Khine H, Wang X. and McManus MT. Polymerase II promoter strength determines efficacy of microRNA adapted shRNAs. PloS One 2011; 6:e26213-20; PMID:22031824; http://dx.doi.org/10.1371/journal.pone.0026213
75. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mat 2013; 12:967-77; PMID:24150415; http://dx.doi.org/10.1038/nmat3765